Lecanemab Long-Term Efficacy and Safety in the Asian Region: A Subgroup Analysis from the Phase 3 Clarity AD Trial
Chen et al
Lecanemab Long-Term Efficacy and Safety in the Asian Region: A Subgroup Analysis from the Phase 3 Clarity AD Trial
